Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2015

View Archived Issues

SKY92 gene expression signature combined with ISS in MM survival prognosis

Transient expression of ZSCAN4 corrects trisomy in cells from people with Down syndrome

Homozygous mutation in PPP1R15B leads to beta-cell dysfunction and diabetes

New financing round at Pharmalink to fund development of phase III program for Nefecon

Nivolumab shows enhanced overall survival in mRCC patients

Genzyme opts into Alnylam Pharmaceuticals' ALN-AT3 hemophilia program

BioCancell advances combination of BC-819 and BCG for bladder cancer

Cellectar Biosciences awarded grant to advance phospholipid drug conjugate platform

REV-002 reduces joint pain in phase IIa trial in acute gout arthritis

DeuteRx completes financing to fund clinical trials of DRX-065 for adrenoleukodystrophy

Arvinas enters license agreement with Genentech to develop therapeutics based on PROTAC technology

Celdara and Pulmatrix receive NIH grant to develop inhaled biologic for IPF

Photocure initiates phase III study of Cysview with blue light cystoscopy in surveillance setting

New approaches for the treatment of diabetes: ECM capsules and bioactive nanocoatings

Novel mitochondrial RNA mutation linked to breast cancer

IAPs show promise for the treatment of M. tuberculosis and M. avium infections

Anthera begins phase III SOLUTION study of oral Sollpura

Encore Vision starts phase I/II trial of EV-06 in presbyopia

Algiax discloses GABA(A) receptor modulators

Bristol-Myers Squibb introduces NS5B inhibitors

Yissum reports mushroom ostreolyisin compositions

Nivalis Therapeutics divulges CFTR modulators

AstraZeneca introduces ENaC modulators

Innate Pharma initiates phase I/II trial of IPH-2201 in combination with ibrutinib for CLL

FDA approves Aristada for schizophrenia

Cardinal Health completes acquisition of J&J's Cordis business

Cobimetinib increases overall survival in patients with melanoma treated with vemurafenib

Gilead's new treatment combination of Letairis and tadalafil gains FDA approval for PAH

Cell Therapy plans European CMA submission for Heartcel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...